Carsten Bönnemann, MD, on Identifying At-Risk Genotypes for DMD Gene Therapy
The senior investigator from NINDS discussed findings investigating serious AEs across different trials.
“Only by coming together with all the sponsors and everyone who is in the trials, were we able to quickly compare the genotypes, compare the events, confirm that the events are strikingly similar in that clinical evolution, that the genotypes are really similar as well. And that lead to identification of the likely offending immunological epitope on that transgene.”
Investigators have elucidated at-risk genotypes for anti-transgene serious adverse events (SAEs) shared across studies of Duchenne muscular dystrophy (DMD) gene therapies by 4 sponsors, Pfizer, Sarepta, Genethon, and Solid Biosciences.
The group’s findings were presented at the
Bönnemann and colleagues hypothesize that patients’ genotypes determine a T-cell mediated immune response to the expressed transgene protein in a cross-reactive immunological material (CRIM)-negative setting. CGTLivespoke with Bönnemann to learn more about the group’s findings as well as their impact on trials investigating DMD gene therapies.
To read more coverage of ASGCT 2022,
REFERENCE
Bönnemann CG, Belluscio BA, Braun S, et al. A collaborative analysis by clinical trial sponsors and academic experts of anti-transgene SAEs in studies of gene therapy for DMD. Presented at: ASGCT 25th Annual Meeting, May 16-19, 2022; Washington DC.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025